Gross margin
71.6% Fiscal year 2025
Rank 85 of 100: higher than 85% of 370 peers (All). strong.
Rank 79 of 100: higher than 79% of 49 peers (Sector). strong.
Median Health Care: 61.8%
Share of revenue left after the direct cost of the products sold.
Health Care · Fundamental analysis
Metrics from daily candles, as of Nov 20, 2026 · Extended universe
Figures in the price bar from TradingView (mostly trailing 12 months) · our fundamental analysis uses the fiscal year
Insulet is a US medical technology company. It makes the Omnipod insulin pump, a tubeless pump worn directly on the skin that makes insulin delivery easier for people with diabetes. It sells mainly in the US and Europe. As of Oct 11, 2026
Insulet primarily develops, manufactures and sells its own systems for continuous insulin delivery for people with insulin-requiring diabetes. The Omnipod platform includes Omnipod 5 with a built-in control algorithm and Omnipod DASH, each with a self-adhesive, tubeless disposable pod. In August 2024 Omnipod 5 received an expanded FDA clearance for adults with type 2 diabetes. In the US, the company supplies wholesalers for the pharmacy channel and also delivers through distribution partners and directly to consumers. It also makes pods for Amgen, which are used in the delivery system for the drug Neulasta.
Automatically summarized from SEC annual report (10-K, filed Feb 18, 2026) (website of the US Securities and Exchange Commission) · reviewed Oct 15, 2026
Our own calculation from the exchange’s daily candles, as of Nov 20, 2026. “All-time” applies since the start of this series, not to the whole market. Changes in percent; the TradingView chart shows prices. “Today” = change of the last trading day versus the previous day. Not investment advice.
Growth, margin, balance sheet, cash flow and dividend compared with the sector – with traffic lights and quality checks in the fundamental analysis. To the fundamental analysis
Insulet Corporation · Sector Health Care · amounts in USD
Source: SEC filings, As of Feb 18, 2026.
For you first Dividend
The company pays no dividend.
Dividend at a glance Dividends and buybacks per year “Dividend” check What matters for dividend investors
For you first Valuation
The P/E is below its own median of the 5 fiscal years before.
With a free account you can see how far – and the same for P/S and price/free cash flow, with the calculation. Sign up free
Valuation against its own history Valuation over time Comparison with the sector What matters for value investors
For you first Growth
How strongly revenue and earnings per share have grown over the years.
“Growth” check Figures over time Consistency What matters for growth investors
For you first Quality
How much of revenue remains and whether profit arrives as cash.
“Quality” check Earnings quality What matters for quality investors
For you first Trading
The overview of this stock shows the trend by timeframe.
To the overview Chart patterns of this stock What matters for traders
Four angles on the annual figures. Each check counts how many disclosed criteria are met – criteria without data do not count. The bars show where the company ranks on each figure among the stocks we cover and within its sector.
Fiscal year to Dec 31, 2025
71.6% Fiscal year 2025
Rank 85 of 100: higher than 85% of 370 peers (All). strong.
Rank 79 of 100: higher than 79% of 49 peers (Sector). strong.
Median Health Care: 61.8%
Share of revenue left after the direct cost of the products sold.
17.5% Fiscal year 2025
Rank 55 of 100: higher than 55% of 470 peers (All). medium.
Rank 53 of 100: higher than 53% of 54 peers (Sector). medium.
Median Health Care: 17.0%
Operating income divided by revenue: what the core business earns before interest and taxes.
9.1% Fiscal year 2025
Rank 40 of 100: higher than 40% of 584 peers (All). medium.
Rank 42 of 100: higher than 42% of 63 peers (Sector). medium.
Median Health Care: 12.9%
Profit after all costs, interest and taxes divided by revenue.
16.3% Fiscal year 2025
Rank 58 of 100: higher than 58% of 544 peers (All). medium.
Rank 64 of 100: higher than 64% of 54 peers (Sector). medium.
Median Health Care: 12.8%
Net income divided by equity at fiscal year end.
7.7% Fiscal year 2025 (total assets at year end)
Rank 67 of 100: higher than 67% of 594 peers (All). strong.
Rank 60 of 100: higher than 60% of 63 peers (Sector). medium.
Median Health Care: 6.6%
Net income divided by total assets at fiscal year end.
47.5% Fiscal year 2025
Rank 67 of 100: higher than 67% of 595 peers (All). strong.
Rank 60 of 100: higher than 60% of 63 peers (Sector). medium.
Median Health Care: 44.2%
Equity as a share of total assets. Usually low for banks.
13.9% Fiscal year 2025
Rank 57 of 100: higher than 57% of 465 peers (All). medium.
Rank 47 of 100: higher than 47% of 61 peers (Sector). medium.
Median Health Care: 14.5%
Free cash flow divided by revenue.
377.7M USD Fiscal year 2025
Operating cash flow minus capital expenditure on property and equipment.
+27.5% per year
Rank 90 of 100: higher than 90% of 578 peers (All). strong.
Rank 96 of 100: higher than 96% of 62 peers (Sector). strong.
Median Health Care: +5.1%
Average growth per year over 3 fiscal years.
+24.5% per year
Rank 86 of 100: higher than 86% of 549 peers (All). strong.
Rank 98 of 100: higher than 98% of 60 peers (Sector). strong.
Median Health Care: +7.8%
Average growth per year over 5 fiscal years.
+26.2% per year
Rank 94 of 100: higher than 94% of 412 peers (All). strong.
Rank 91 of 100: higher than 91% of 50 peers (Sector). strong.
Median Health Care: +9.3%
Average growth per year over 10 fiscal years.
+267.7% per year
Rank 100 of 100: higher than 100% of 437 peers (All). strong.
Rank 99 of 100: higher than 99% of 54 peers (Sector). strong.
Median Health Care: +5.0%
Growth of earnings per share per year, adjusted for stock splits.
+103.4% per year
Rank 98 of 100: higher than 98% of 399 peers (All). strong.
Rank 97 of 100: higher than 97% of 47 peers (Sector). strong.
Median Health Care: +8.3%
Growth of earnings per share per year, adjusted for stock splits.
7 of 9 Fiscal year 2025
Rank 69 of 100: higher than 69% of 310 peers (All). strong.
Rank 65 of 100: higher than 65% of 47 peers (Sector). medium.
Median Health Care: 6.0 of 9
Nine yes/no tests on profit, cash flow, debt, liquidity and efficiency compared with the prior year.
0.63 at fiscal year end
Rank 52 of 100: lower than 52% of 486 peers (All). medium.
Rank 53 of 100: lower than 53% of 50 peers (Sector). medium.
Median Health Care: 0.66
Long-term financial debt divided by equity.
2.81 at fiscal year end
Rank 83 of 100: higher than 83% of 513 peers (All). strong.
Rank 79 of 100: higher than 79% of 63 peers (Sector). strong.
Median Health Care: 1.58
Current assets divided by current liabilities.
+9.0% in 5 years
Rank 21 of 100: lower than 21% of 507 peers (All). weak.
Rank 6 of 100: lower than 6% of 59 peers (Sector). weak.
Median Health Care: −4.3%
Change in diluted share count. Negative = share buybacks, positive = new shares.
Last fiscal year compared with the one before. Returns and revenue per total assets use total assets at the start of the year; leverage = long-term financial debt divided by total assets at year end; new shares via the average diluted share count.
Price-based criteria (P/E, dividend yield) are shown to signed-in users.
Computed automatically from SEC annual reports – not investment advice. Describes the reported figures; points are not a rating of the stock. Rank 0–100 against the 239 stocks we cover and against the sector (from 5 peers); the stronger side is always on the right.
Summarized from the lights below. Describes the reported figures – not a recommendation to buy or sell.
No reported values for “Dividend per share” in this interval.
No reported values for “Dividend per share” in this interval.
Fiscal year 2025 (Jan 1, 2025 – Dec 31, 2025): Revenue 2.7B USD · Net income 247.1M USD · Net margin 9.1%
How has it gone since the last annual report?
Revenue in the quarter to Sep 2026 +19.2% vs. the same quarter a year earlier; grown for at least 16 quarters in a row.
| Quarter | Revenue | vs. year ago | Net income | Margin |
|---|---|---|---|---|
| Jul–Sep 26 | 842.0M | +19.2% | 141.1M | 16.8% |
| Apr–Jun 26 | 801.7M | +23.5% | 95.0M | 11.8% |
| Jan–Mar 26 | 761.7M | +33.9% | 91.1M | 12.0% |
| Oct–Dec 25* | 783.8M | +31.2% | 101.6M | 13.0% |
| Jul–Sep 25 | 706.3M | +29.9% | 87.6M | 12.4% |
| Apr–Jun 25 | 649.1M | +32.9% | 22.5M | 3.5% |
| Jan–Mar 25 | 569.0M | +28.8% | 35.4M | 6.2% |
| Oct–Dec 24* | 597.5M | +17.2% | 100.7M | 16.9% |
Trailing 12 months = last fiscal year + the period since the start of the current fiscal year − the same period a year earlier, each from the first filing. P/E, PEG and the quality checks still use the last fiscal year.
Each quarter is compared with the same quarter a year earlier.
* derived: fiscal year minus the first 9 months.
As of: 12 months to Sep 30, 2026, filed on Nov 4, 2026 · Source: SEC filings (10-Q, 10-K)
Does the profit arrive as cash?
Profit is backed by cash; interest is well covered.
| FY | Cash flow ÷ profit | Interest coverage | Tax rate |
|---|---|---|---|
| 2025 | 2.30x | 8.0x | 27.2% |
| 2024 | 1.03x | 7.2x | −39.3% |
| 2023 | 0.71x | 6.1x | 3.9% |
| 2022 | over 10x | 1.0x | 53.1% |
| 2021 | negative | 2.0x | 18.0% |
How it is rated: cash flow ÷ profit from 1.0 “backed by cash”, below 0.8 “profit well above the cash coming in”; interest coverage from 5 “well covered”, below 2 “thinly covered”. The tax rate is only shown.
Cash flow ÷ profit uses group profit incl. minority interests, because cash flow also covers the whole group. Profit before tax as reported to the SEC, otherwise approximated. “3 years” = sums of the last three fiscal years – only if every year is reported and the figures have the same origin; for cash flow only with a profit in every year.
As of fiscal year 2025 · Source: SEC filings
How even were the last years?
In 10 fiscal years 2 loss years and no year with lower revenue.
| FY | Revenue vs. prior year | Net margin |
|---|---|---|
| 2025 | +30.7% | 9.1% |
| 2024 | +22.1% | 20.2% |
| 2023 | +30.0% | 12.2% |
| 2022 | +18.8% | 0.4% |
| 2021 | +21.5% | 1.5% |
| 2020 | +22.5% | 0.8% |
| 2019 | +30.9% | 1.6% |
| 2018 | +21.6% | 0.6% |
| 2017 | +26.4% | −5.8% |
| 2016 | +39.1% | −7.9% |
Loss year: net income below zero. Lower revenue: revenue below the prior year. Range: highest minus lowest net margin; margins beyond ±200% do not count. No score – only the reported figures.
As of fiscal years 2016–2025 · Source: SEC filings
Where the money of a fiscal year goes and how margins, returns, balance sheet, cash flow and share count developed over up to 10 years. Each chart has one sentence saying what the trend shows.
Of 100 USD of revenue, 71.6 USD gross profit, 17.5 USD operating income and 9.1 USD net income remained.
| Item | Amount | of revenue |
|---|---|---|
| Revenue | 2.7B USD | 100.0% |
| Gross profit | 1.9B USD | 71.6% |
| Cost of revenue | 768.2M USD | 28.4% |
| Operating income | 473.8M USD | 17.5% |
| Research & development | 301.1M USD | 11.1% |
| Other operating expenses | 1.2B USD | 43.0% |
| Net income | 247.1M USD | 9.1% |
| Interest expense | 59.4M USD | 2.2% |
| Taxes | 92.4M USD | 3.4% |
| Other | 74.9M USD | 2.8% |
Taxes, interest and other items are not available separately in the SEC data; they are combined as the difference.
The operating margin rose in 5 years from 5.7% to 17.5%.
Gross marginOperating marginNet marginReturn on equity rose in 5 years from 1.1% to 16.3%.
Return on equityReturn on assetsThe equity ratio rose in 5 years from 32.2% to 47.5%.
EquityLong-term debt in USD Long-term debt, depending on the filing, includes the current portion or leases. Definition changes: some years use a different debt tag.The current ratio fell in 5 years from 6.01 to 2.81.
Current ratioFree cash flow rose in 5 years from −45.0M USD to 377.7M USD.
Operating cash flowCapital expenditureFree cash flow in USDThe share count rose in 5 years by 9.0% – more new shares were issued than repurchased (dilution).
Diluted share countFrom annual reports filed with the SEC (10-K, 20-F, 40-F) as first reported, share count adjusted for splits; obvious filing errors (e.g. wrong unit, outliers against both neighbouring years) are hidden. Describes the reported figures – not investment advice.
Up to three metrics stacked over the same fiscal years – so you see at a glance whether they rise together or drift apart. Point at a year to read it in every panel.
Revenue rose in 5 years from 904.4M USD to 2.7B USD.
PODD in USDThe net margin rose in 5 years from 0.8% to 9.1%.
PODD Sector today 13.2% Mark in the latest year: today’s median of the Health Care sector as in the sector comparison (each latest fiscal year). We do not have earlier medians.The free cash flow margin rose in 5 years from −5.0% to 13.9%.
PODD Sector today 14.7%Source: SEC filings, fiscal years up to Dec 31, 2025. The same figures as in the sections of this page, per fiscal year as first reported. Describes the reported figures – not investment advice.
How reliable is the dividend?
The company pays no dividend.
As of fiscal year 2025 · Source: SEC filings
Valued higher or lower than usual?
The P/E is below its own median of the 5 fiscal years before.
With a free account you can see how far – and the same for P/S and price/free cash flow, with the calculation. Sign up free
Source: SEC filings and our daily candles
How much the company returns to its shareholders – as dividends or by repurchasing its own shares – and whether free cash flow supports it.
Over 3 years, 59.6M USD went back to shareholders, 100% of it through share repurchases. That is 8% of the free cash flow of those years.
Dividends paidShare repurchasesNew shares issued (including employee plans)Free cash flow in USDDividends paid, repurchases and new shares issued from the cash flow statement of annual reports filed with the SEC (as first reported). Describes the reported figures – not investment advice.
Price-based valuation (P/E, P/S, price/free cash flow and dividend yield per fiscal year, compared with its own average) for signed-in users. Log in
Insulet Corporation next to 8 stocks of the sector Health Care we cover that are closest in revenue. Click a column header to sort the table.
| Symbol | Revenue (FY) | Growth 5 yrs | Gross margin | Op. margin | Net margin | ROE | Equity ratio | FCF margin | Piotroski |
|---|---|---|---|---|---|---|---|---|---|
| SYK Stryker Corporation | 25.1B USD | +11.8% | 64.0% | 19.5% | 12.9% | 14.5% | 46.9% | 17.1% | 6/9 |
| DHR Danaher Corporation | 24.6B USD | +2.0% | 59.1% | 19.1% | 14.7% | 6.9% | 62.9% | 21.4% | 7/9 |
| REGN Regeneron Pharmaceuticals | 14.3B USD | +11.0% | – | 24.9% | 31.4% | 14.4% | 77.1% | 28.4% | – |
| VRTX Vertex Pharmaceuticals | 12.0B USD | +14.1% | 86.2% | 34.8% | 32.9% | 21.2% | 72.8% | 26.6% | – |
| ISRG Intuitive Surgical | 10.1B USD | +18.2% | 66.0% | 29.3% | 28.4% | 16.0% | 87.1% | 24.7% | – |
| PODD Insulet Corporation this stock | 2.7B USD | +24.5% | 71.6% | 17.5% | 9.1% | 16.3% | 47.5% | 13.9% | 7/9 |
| MRNA Moderna | 1.9B USD | +19.3% | 55.3% | −158.1% | −145.2% | −32.6% | 70.1% | −106.2% | 2/9 |
| NVAX Novavax | 1.1B USD | +18.8% | 93.5% | 40.3% | 39.2% | – | −10.9% | −22.3% | 5/9 |
| IOVA Iovance Biotherapeutics | 263.5M USD | – | 34.3% | −153.1% | −148.4% | −56.0% | 76.5% | −127.6% | – |
| Median of the sector 27 symbols | 44.3B USD | +9.4% | 67.9% | 17.8% | 13.2% | 14.3% | 38.5% | 14.7% | 7/9 |
Growth 5 yrs = revenue growth per year over 5 fiscal years · Op. margin = operating margin · ROE = return on equity · FCF = free cash flow · Piotroski = F-Score (only with all 9 criteria).
Compare with the closest peer in the sector PODD next to MRNA – quality checks, metrics and depth side by side.
Figures of the last fiscal year from SEC annual reports (peers as of Nov 22, 2026). Median across all companies of the sector we cover (from 5 stocks; several share classes of one company count once). Signed-in users also see P/E, P/S and dividend yield in the comparison. Describes the reported figures – not investment advice.
Each light follows a simple, disclosed rule. The comparison is with the sector median Sector medianThe middle value of all companies in a sector: half are above it, half below. Unlike the average, single outliers hardly distort it.Example: Margins 4%, 8%, 10%, 12%, 60% → median 10%, average 18.8%.More in the Academy: Lesson putting the P/E in context of all 26 symbols in the Health Care sector on our list (current members of the S&P 500 and other lists).
+24.5% per year, last 5 years
Sector Health Care: median +8.5% (25 symbols)
What does this mean? Revenue: over 5 years it grew by 24.5% per year on average – at least as fast as the median company in the sector (+8.5%).
Light rule: Green: grows at least as fast as the sector median (without a sector comparison: grows) · Yellow: grows more slowly · Red: shrinks.
+105.2% per year, last 5 years
Sector Health Care: median +5.5% (20 symbols)
per share: +103.4% per year (5 years, split-adjusted)
What does this mean? Total net income: over 5 years it grew by 105.2% per year on average – at least as fast as the median company in the sector (+5.5%).
Light rule: Green: grows at least as fast as the sector median (without a sector comparison: grows) · Yellow: grows more slowly · Red: shrinks.
9.1% last fiscal year
Sector Health Care: median 13.9% (26 symbols)
What does this mean? Of every 100 USD in revenue, 9.12 USD remained as profit – less than the median company in the sector (13.9%). Five years ago the margin was 0.8%.
Light rule: Green: at least the sector median (without a sector comparison: profit) · Yellow: profit, but below the median · Red: loss.
0.61 latest balance sheet
Sector Health Care: median 0.66 (19 symbols)
What does this mean? For every 1 USD of equity there is 0.61 USD of financial debt – no more than the median company in the sector (0.66). More debt amplifies good and bad years alike.
Light rule: Green: at most the sector median · Yellow: up to twice the median · Red: more than twice · Gray: without a sector comparison.
– Dividend / earnings per share
Sector Health Care: median 56% (16 symbols)
What does this mean? The loaded SEC filings of the last two fiscal years contain no dividend per share. Either the company pays none, or it reports it under a different tag.
Light rule: Green: up to 60% of earnings · Yellow: up to 100% · Red: more than earnings or a dividend despite a loss · Gray for real estate (REITs). The sector median is for comparison only.
8 of 10 fiscal years with a profit
What does this mean? In 8 of the last 10 fiscal years the bottom line showed a profit. 2 years ended with a loss.
Light rule: Green: profit in every year · Yellow: one loss year · Red: several loss years (at least 3 years needed).
| Year | End | Revenue | Net income | Margin | Earnings per share | Dividend per share | Payout |
|---|---|---|---|---|---|---|---|
| 2025 | Dec 31, 2025 | 2.7B | 247.1M | 9.1% | 3.48 | – | – |
| 2024 | Dec 31, 2024 | 2.1B | 418.3M | 20.2% | 5.78 | – | – |
| 2023 | Dec 31, 2023 | 1.7B | 206.3M | 12.2% | 2.94 | – | – |
| 2022 | Dec 31, 2022 | 1.3B | 4.6M | 0.4% | 0.07 | – | – |
| 2021 | Dec 31, 2021 | 1.1B | 16.8M | 1.5% | 0.24 | – | – |
| 2020 | Dec 31, 2020 | 904.4M | 6.8M | 0.8% | 0.10 | – | – |
| 2019 | Dec 31, 2019 | 738.2M | 11.6M | 1.6% | 0.19 | – | – |
| 2018 | Dec 31, 2018 | 563.8M | 3.3M | 0.6% | 0.05 | – | – |
| 2017 | Dec 31, 2017 | 463.8M | −26.8M | −5.8% | −0.46 | – | – |
| 2016 | Dec 31, 2016 | 367.0M | −28.9M | −7.9% | −0.48 | – | – |
| Quarter | End | Revenue | Net income | Margin | Earnings per share | Dividend per share | Payout |
|---|---|---|---|---|---|---|---|
| Q3/26 | Sep 30, 2026 | 842.0M | 141.1M | 16.8% | 2.03 | – | – |
| Q2/26 | Jun 30, 2026 | 801.7M | 95.0M | 11.8% | 1.37 | – | – |
| Q1/26 | Mar 31, 2026 | 761.7M | 91.1M | 12.0% | 1.30 | – | – |
| Q4/25* | Dec 31, 2025 | 783.8M | 101.6M | 13.0% | – | – | – |
| Q3/25 | Sep 30, 2025 | 706.3M | 87.6M | 12.4% | 1.24 | – | – |
| Q2/25 | Jun 30, 2025 | 649.1M | 22.5M | 3.5% | 0.32 | – | – |
| Q1/25 | Mar 31, 2025 | 569.0M | 35.4M | 6.2% | 0.50 | – | – |
| Q4/24* | Dec 31, 2024 | 597.5M | 100.7M | 16.9% | – | – | – |
| Q3/24 | Sep 30, 2024 | 543.9M | 77.5M | 14.2% | 1.08 | – | – |
| Q2/24 | Jun 30, 2024 | 488.5M | 188.6M | 38.6% | 2.59 | – | – |
| Q1/24 | Mar 31, 2024 | 441.7M | 51.5M | 11.7% | 0.73 | – | – |
| Q4/23* | Dec 31, 2023 | 509.8M | 103.3M | 20.3% | – | – | – |
* Q4 derived: fiscal year minus the 9-month value (EPS cannot be derived this way); may be distorted by restatements.
How we calculate: values as first reported to the SEC (later corrections are left out), a fixed order of reporting tags per figure, partial sums are never added up. Growth per year Growth per year (CAGR)The average annual growth rate over several years, as if the value had grown equally strongly every year. Individual good or bad years even out in it.Example: Revenue €100m → €161m in 5 years → (161 ÷ 100) to the power of 1/5 − 1 = 10% per year.More in the Academy: Lesson debt, dividends and growth over 5 years (otherwise 3 years). Quarters are labeled by the calendar quarter in which they end.
Information only – does not affect the other analysis methods, not investment advice.
| Period | Purchases | Sales | Net |
|---|---|---|---|
| 3 months | $00 people | $00 people | $0 |
| 6 months | $1.1M3 people | $59.9K1 person | +$1.0M |
| 12 months | $2.9M4 people | $602.4K2 people | +$2.3M |
Source: mandatory filings with the SEC (Form 4), open-market purchases and sales only. General information, not investment advice.
3 of 26 tracked superinvestors report a position.
| Investor | Weight in portfolio | vs. previous quarter | As of |
|---|---|---|---|
| Paul Tudor Jones Tudor Investment Corp | 0.2% | +113.9% increased | Q3 2026 |
| Renaissance Technologies | < 0.1% | +55.1% increased | Q3 2026 |
| Bridgewater Associates | < 0.1% | −47.0% reduced | Q3 2026 |
Source: 13F filing with the US Securities and Exchange Commission, latest filing dated Nov 16, 2026. It shows positions at quarter end and is filed up to 45 days later – today the positions may be several months old. It covers only securities traded on US exchanges, without short positions; securities traded only abroad and cash are not included.
We do not calculate a trend score for symbols in the extended universe.
ATR ATR (Average True Range)The average range per trading day over the last 14 days. It makes distances comparable, whether a stock costs 10 or 1,000.Example: ATR 2.50 at a price of 100: 0.4 ATR is 1.00, i.e. 1%.More in the Academy: Lesson ATR and moving averages as price values only when logged in.
No recent news found. News is loaded automatically three times a day for trend stocks, symbols with a current Elliott setup and favorites.
No posts on PODD yet – log in to join the discussion.
Posts are opinions of users and only visible after logging in. Community rules